Hims & Hers Health Inc. (NYSE: HIMS) announced the launch of generic semaglutide through its platform in Canada, marking the company's first international generic GLP-1 offering. The treatment is available starting at $149 CAD per month through personalized treatment plans.

The generic semaglutide is authorized by Health Canada for managing Type 2 diabetes and may be prescribed off-label for weight management at healthcare providers' discretion. Hims & Hers Canada does not currently offer treatment services for Type 2 diabetes.

According to Canadian government data referenced in the announcement, nearly two-thirds of Canadian adults are overweight or living with obesity. The company stated that cost has been a barrier to treatment access in the Canadian market.

"Bringing generic semaglutide to Canada is a meaningful milestone, but it's also a signal of something larger: our conviction that the model we've built in the United States can and should serve customers around the world," said Mike Chi, Chief Operating Officer of Hims & Hers.

The platform provides eligible Canadian customers access to personalized care plans that may include generic semaglutide or branded options, along with ongoing care team access and resources focused on nutrition, movement, and sleep. Canadian customers are served by Canadian healthcare providers.

Dr. Sandy Van, Obesity Medicine Specialist and Chief Medical Officer for Hims & Hers Canada, stated that the launch represents "a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient."

The information is based on a company press release statement.